SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is surging following FDA approval of Bysanti (milsaperidone) for bipolar I disorder and schizophrenia, with the community anticipating a major valuation re-rating and potential buyout due to its blockbuster market potential alongside the company's Tradipitant pipeline targeting GLP-1 induced nausea.

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

Crowdstrike is trending following a sector-wide sell-off driven by fears that Anthropic's new Claude Code Security tool will disrupt traditional cybersecurity, sparking intense community debate over CRWD's valuation versus its distinct role in endpoint and cloud protection against evolving AI threats.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corp - ADR

Amarin is trending as community discussion focuses on its strategic exclusion from China's national drug list, aiming to preserve pricing power, while investors keenly await a pending U.S. Supreme Court decision on its patent infringement case. This coincides with anticipated positive financial results and ongoing speculation about a potential acquisition as the company positions for a turnaround.

Blue Owl Capital, Inc. operates as an alternative asset management firm. It provides investors access to asset management capital solutions through its Direct Lending and GP Capital Solutions products. The company offers a platform of capital solutions to both middle market companies and large alternative asset managers. The company was founded by Doug Irving Ostrover, Michael Rees and Craig W.Packer in 2009 and is headquartered in New York, NY.

Blue Owl Capital Inc - Ordinary Shares - Class A

Blue Owl Capital is trending due to community debate over reported challenges in financing a major AI data center and a strategic shift in capital redemption for a retail private credit fund, fueling broader liquidity concerns in the sector while attracting value investors.

Starfighters Space, Inc. is engaged in the research and development of space flight, pilot training, and aeronautics programs. It operates the commercial fleet Lockhead F-104s. The company was founded by Rick Svetkoff on September 6, 2022 and is headquartered in Kennedy Space Center, FL.

Starfighters Space Inc

Starfighters Space (FJET) is driving significant investor conversation and high volatility as its team rings the NYSE Opening Bell, following successful wind tunnel testing for its STARLAUNCH I rocket. The community is intensely debating its potential for a short squeeze and its role in the expanding space and defense sectors ahead of next week's NYSE Space Summit, with many anticipating further upward movement.

Rich Sparkle Holdings Ltd. engages in the provision of financial printing and corporate services. The firm offers typesetting, proofreading, translation, design, and printing of listing documents, financial reports, fund documents, circulars, and announcements. It also delivers advisory services, such as conducting internal control assessment and environmental, social and governance performance evaluation, and other services including provision of co-working space. The company was founded in 2016 and is headquartered in Hong Kong.

Rich Sparkle Holdings Ltd.

Rich Sparkle Holdings Limited

Rich Sparkle Holdings (ANPA) is trending with extreme volatility driven by its acquisition of a TikTok icon's core company and a recent private placement. Community discussion is polarized between a speculative short squeeze, drawing comparisons to other "Hong Kong low float" stocks, and fundamental concerns over its soaring valuation amidst share dilution.

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Kyverna Therapeutics Inc.

Kyverna Therapeutics (KYTX) is trending following positive Phase 2 data for its miv-cel CAR-T therapy in Stiff Person Syndrome, meeting all primary and secondary endpoints and supporting a future BLA filing. The community highlights the therapy's groundbreaking potential in autoimmune diseases, robust cash runway, and significant analyst price target increases, fueling strong long-term optimism amidst recent stock fluctuations.

Wingstop, Inc. is a franchisor and chicken wings-focused restaurant. The firm is engaged in the flavor business offering cooked-to-order, hand-sauced, and tossed classic and boneless wings, tenders and chicken sandwiches in flavors, with signature sides, such as its seasoned fries and house made ranch and bleu cheese dips. The company was founded in 1994 and is headquartered in Dallas, TX.

Wingstop Inc

Wingstop is trending after strong earnings and an upgraded growth outlook fueled analyst upgrades, though many in the community debate if its rapid expansion justifies the current high valuation amidst broader restaurant sector concerns.

SentinelOne, Inc. engages in the provision of endpoint security software that detects, models, and predicts threat behavior to block attacks on any computing device. Its services include vigilance, support, and training. The company was founded by Tomer Weingarten and Almog Cohen in 2013 and is headquartered in Mountain View, CA.

SentinelOne Inc - Ordinary Shares - Class A

SentinelOne Inc

SentinelOne is trending as a bullish Citron Research report highlights its leadership in autonomous AI agent security through its Prompt Security acquisition, sparking debate among investors frustrated by its perceived undervaluation. The community emphasizes the company's strong, debt-free fundamentals and recent government contract authorizations, arguing its AI-native solutions are crucial against escalating cyber threats and signaling potential for a significant rebound or acquisition.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

The VanEck Semiconductor ETF (SMH) is trending due to robust demand for AI infrastructure and surging memory chip prices, which are propelling its major holdings like TSM and MU. While many investors see it as a strong play, others in the community view its rapid, 'parabolic' ascent as an 'AI bubble' poised for correction amidst overvaluation concerns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Jupiter Asset Management Ltd. Purchases 129,971 Shares of Halozyme Therapeutics, Inc. $HALO

Jupiter Asset Management Ltd. boosted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 19.4% in the 3rd quarter, according to its most recent filing with the...

Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $90.00

Benchmark increased their price target on Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a "buy" rating in a research report on Thursday...

Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $75.00 at Wells Fargo & Company

Wells Fargo & Company increased their price target on Halozyme Therapeutics from $65.00 to $75.00 and gave the company an "equal weight" rating in a research report on Thursday...

Halozyme Therapeutics (NASDAQ:HALO) Stock Price Down 8.7% Following Weak Earnings

Halozyme Therapeutics (NASDAQ:HALO) Stock Price Down 8.7% on Disappointing Earnings...

Halozyme's Q4 Earnings Miss, Higher Royalties Drive Y/Y Revenues

HALO swings to Q4 loss on acquisition charge, but revenues surge 52%, fueled by royalties and product sales and top estimates.

Halozyme Therapeutics, Inc. $HALO Shares Sold by Hodges Capital Management Inc.

Hodges Capital Management Inc. trimmed its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 21.0% during the third quarter, according to its most recent filing with the...

Halozyme Therapeutics (NASDAQ:HALO) Announces Quarterly Earnings Results, Misses Expectations By $2.16 EPS

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) issued its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing...

Halozyme Therapeutics Q4 Earnings Call Highlights

Halozyme Therapeutics (NASDAQ:HALO) executives highlighted what they described as a significant and value-creating 2025, pointing to accelerating royalty growth from ENHANZE-enabled products...

Here's What Key Metrics Tell Us About Halozyme Therapeutics (HALO) Q4 Earnings

The headline numbers for Halozyme Therapeutics (HALO) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Halozyme Therapeutics (HALO) Reports Q4 Loss, Tops Revenue Estimates

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of -111.16% and +0.70%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

HALO
Halozyme Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest HALO News

HALOHalozyme Therapeutics Inc.